Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | ELANE | P08246 | 2/20 | 0.44 |
| ▸ | RAD52 | P43351 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | NQO2 | P16083 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | DHODH | Q02127 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8900146 | 0.85 | MAPKAPK2 (0.43) | LMNAKDM4EALDH1A1MAPTMEN1 | |
| SCHEMBL8284883 | 0.84 | LMNA (0.47) | LMNAELANERAD52SMN1; SMN2KDM4E | |
| SCHEMBL11261496 | 0.81 | LMNA (0.44) | LMNAELANERAD52SMN1; SMN2KDM4E | |
| SCHEMBL11219383 | 0.81 | KDM4E (0.58) | LMNAELANERAD52SMN1; SMN2KDM4E | |
| SCHEMBL3245979 | 0.81 | ADORA2A (0.51) | LMNARAD52SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL13982551 | 0.81 | LMNA (0.45) | LMNAELANERAD52SMN1; SMN2KDM4E | |
| SCHEMBL24108918 | 0.77 | KDM4E (0.67) | LMNAKDM4EALDH1A1HSD17B10L3MBTL1 | |
| SCHEMBL12033647 | 0.77 | MEN1 (0.53) | LMNASMN1; SMN2KDM4EALDH1A1HSD17B10 | |
| SCHEMBL11201236 | 0.77 | KDM4E (0.44) | LMNARAD52SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL3760247 | 0.76 | LMNA (0.61) | LMNAELANERAD52SMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12030857-B2 | Glucose uptake inhibitors | KADMON CORPORATION, LLC (US) | 2024-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12030857-B2 | Glucose uptake inhibitors | SLC2A1, SLC2A4, SLC2A2 | LMNA 4856/4885ELANE 4630/4885RAD52 4608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.